Filtered By:
Cancer: Oral Cancer
Drug: Estradiol

This page shows you your search results in order of date.

Order by Relevance | Date

Total 20 results found since Jan 2013.

Fight Aging! Newsletter, August 7th 2023
In conclusion, here, we demonstrate a novel mechanism for ESC-EVs to protect cells from senescence. However, whether ESC-EVs rejuvenate aged mice via miR-15b-5p and miR-290a-5p remains unknown. Next, we plan to use miR-15b-5p and miR-290a-5p antagonists while treating aged mice with ESC-EVs to further investigate the mechanism by which ESC-EVs resist aging in vivo. « Back to Top Fatty Acid Metabolism as a Commonality in Different Approaches to Slowing Aging https://www.fightaging.org/archives/2023/08/fatty-acid-metabolism-as-a-commonality-in-different-approaches-to-slowing-aging/ It seems...
Source: Fight Aging! - August 6, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

The WHO claims estrogens are 'carcinogenic': is this true?
Climacteric. 2023 Apr 17:1-8. doi: 10.1080/13697137.2023.2196002. Online ahead of print.ABSTRACTEstrogens are in the list of carcinogenic chemicals from the World Health Organization (WHO). However, estrogens require additional factors such as stromal factors or progestogens to increase the ratio of proliferation/apoptosis for initiation of replication errors and consequent mutations to occur. These mutations require at least 5-10 years to develop into clinically detectable cancer, whereby this review is focused on breast cancer. The US National Cancer Institute highlighted a second mechanism of carcinogenicity: certain es...
Source: Climacteric - April 17, 2023 Category: Geriatrics Authors: X Ruan A O Mueck Source Type: research

Effects of isoflavone supplementation on endometrial thickness, endometrial hyperplasia, and cancer in ovariectomized cats
This study aimed to examine the effects of isoflavone supplementation on endometrial hyperplasia, endometrial thickness, and cancer in ovariectomized cats. Fifteen adult cats were neutered, and then treatment was initiated. Subcutaneous injection of estradiol (0.5 μg) in sesame oil (100 μL) was done for 30 days in estradiol-treated cats. Isoflavone-treated cats ingested a single oral tablet of soy extract for 30 days, while the controls received subcutaneous injections of the vehicle and oral placebo for 30 days. Histopathological findings of hematoxylin and eosin-stained sections showed a significant difference between ...
Source: Cancer Control - May 20, 2022 Category: Cancer & Oncology Authors: Mona Negadmonfared Mona Negadmonfared Reza Narenji Sani Sahar Ghaffari Khaligh Sahar Ghaffari Khaligh Farzad Hayati Farzad Hayati Source Type: research

Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause
Expert Rev Clin Pharmacol. 2022 Mar 21. doi: 10.1080/17512433.2022.2054413. Online ahead of print.ABSTRACTINTRODUCTION: Estrogens used in women's healthcare have been associated with increased risks of venous thromboembolism (VTE) and breast cancer. Estetrol (E4), an estrogen produced by the human fetal liver, has recently been approved for the first time as a new estrogenic component of a novel combined oral contraceptive (E4/drospirenone [DRSP]) for over a decade. In phase 3 studies, E4/DRSP showed good contraceptive efficacy, a predictable bleeding pattern, and a favorable safety and tolerability profile.AREAS COVERED: ...
Source: Clinical Genitourinary Cancer - March 21, 2022 Category: Cancer & Oncology Authors: C éline Gerard Jean-Fran çois Arnal Maud Jost Jonathan Douxfils Fran çoise Lenfant Coralie Fontaine Ren é Houtman David F Archer Robert L Reid Rogerio A Lobo Ulysse Gaspard Herjan J T Coelingh Bennink Mitchell D Creinin Jean-Michel Foidart Source Type: research

Pharmacokinetic Interaction Between the MEK1/MEK2 Inhibitor Trametinib and Oral Contraceptives Containing Norethindrone and Ethinyl Estradiol in Female Patients With Solid Tumors
Clin Pharmacol Drug Dev. 2022 Feb 14. doi: 10.1002/cpdd.1052. Online ahead of print.ABSTRACTThis phase 1 postapproval study assessed the effect of the mitogen-activated protein kinase kinase enzyme 1/enzyme 2 inhibitor trametinib (2 mg once daily, repeat dosing) on the pharmacokinetics of combined oral contraceptives (COCs) containing norethindrone (NE; 1 mg daily) and ethinyl estradiol (EE; 0.035 mg daily) in 19 female patients with solid tumors. Compared with NE/EE administered without trametinib, NE/EE administered with steady-state trametinib was associated with a clinically nonrelevant 20% increase in NE exposure (are...
Source: Clinical Lung Cancer - February 14, 2022 Category: Cancer & Oncology Authors: Hendrik-Tobias Arkenau Donatienne Taylor Xiaoying Xu Shripad Chitnis Casilda Llacer-Perez Kathleen Moore Prasanna Kumar Nidamarthy Palanichamy Ilankumaran Judith De Vos-Geelen Source Type: research

Regioselective synthesis, physicochemical properties and anticancer activity of 2-aminomethylated estrone derivatives
In this study, novel 2-aminomethylated estrone (E) and estradiol (E2) derivatives structurally related to 2ME2 were synthesized, and their physicochemical properties as well as their in vitro cytotoxic effects were investigated in the hope to find more selective antiproliferative agents with improved pharmacokinetic profile. The target compounds were synthesized from 2-dimethylaminomethylated E obtained regioselectively by a three-component Mannich reaction. Quaternization with methyl iodide followed by reacting the ammonium salt with various dialkyl and alicyclic secondary amines afforded the desired products in good yiel...
Source: Mol Biol Cell - January 29, 2022 Category: Molecular Biology Authors: Barnab ás Molnár Njangiru Isaac Kinyua Gerg ö Mótyán P éter Leits Istv án Zupkó Ren áta Minorics Gy örgy T Balogh Éva Frank Source Type: research

Misoprostol and estradiol to enhance visualization of the transformation zone during cervical cancer screening: An integrative review
In conclusion, Oral estradiol, intravaginal estradiol, and intravaginal misoprostol can be used to convert Type 3 TZ to Types 1 or 2. Intravaginal misoprostol is well tolerated and more feasible in LMICs due to availability and shorter treatment schedule compared to oral or intravaginal estradiol.PMID:34952401 | DOI:10.1016/j.ejogrb.2021.11.431
Source: Reproductive Biology - December 24, 2021 Category: Reproduction Medicine Authors: Simon M Manga Kaitlyn D Kincaid Teresa K L Boitano Alan T Tita Isabel C Scarinci Warner K Huh Margaret I Liang Source Type: research